An Unusual Timeline of Nivolumab-Induced Vitiligo in a Patient with Melanoma

Renat Ahatov, Allison Good, Lindy Ross

Research output: Contribution to journalArticlepeer-review


Vitiligo, manifested by skin hypopigmentation, is an autoimmune disorder of the skin due to the autoimmune destruction of melanocytes. Nivolumab, which is a programmed cell death–1 receptor inhibitor, is a well-known therapy for melanoma. Nivolumab-induced vitiligo has been described in literature, explained by destruction of non-cancerous melanocytes. This is considered a favorable response, due to a correlated stronger immune response against tumor cells. The average onset of the vitiligo is reported to be 5.2 months after starting the therapy, with a maximum reported onset being 9 months. We present a 52-year-old male patient whose initial vitiligo presentation occurred a year after starting the therapy and has continued for months after concluding Nivolumab therapy.

Original languageEnglish (US)
Pages (from-to)65-68
Number of pages4
JournalSKIN: Journal of Cutaneous Medicine
Issue number1
StatePublished - Jan 17 2022
Externally publishedYes

ASJC Scopus subject areas

  • Dermatology


Dive into the research topics of 'An Unusual Timeline of Nivolumab-Induced Vitiligo in a Patient with Melanoma'. Together they form a unique fingerprint.

Cite this